NCT06883695View on ClinicalTrials.gov

A Phase Ⅰ Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 8, 2025

Primary Completion Date

June 17, 2025

Study Completion Date

October 31, 2025

Conditions

Rheumatoid Arthritis

Interventions

DRUG

SHR-3045 Injection

SHR-3045 injection.

DRUG

SHR-3045 Placebo Injection

SHR-3045 placebo injection.

Trial Locations (1)

200080

Shanghai General Hospital, Shanghai

All Listed Sponsors

lead

Guangdong Hengrui Pharmaceutical Co., Ltd

INDUSTRY

NCT06883695 - A Phase Ⅰ Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Pharmacodynamics of SHR-3045 in Healthy Subjects | Biotech Hunter | Biotech Hunter